Pertussis Market Set to Reach USD 5,000 Million by 2036

DelveInsight's "Pertussis Market Insights, Epidemiology and Market Forecast 2036" report delivers an in-depth understanding of pertussis, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the pertussis market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the Pertussis Market Report
• The pertussis market size in the leading markets (US, EU4, UK, and Japan) was found to be approximately USD 4,000 million in 2025, and is projected to reach approximately USD 5,000 million by 2036, growing at a CAGR of 2.7% during 2026-2036.
• The US market alone was estimated at nearly USD 3,200 million in 2025, expected to grow further with the launch of emerging vaccines and label expansions of current therapies; Spain recorded the lowest market share among the 7MM in 2025.
• The US accounted for the highest share of pertussis cases in the 7MM in 2025, representing 60% of total cases, while the total vaccinated population in the US was estimated at approximately 20 million in 2025, projected to increase over the forecast period.
• Rising incidence of pertussis - driven by inadequate immunization and waning immunity among vaccinated groups - is fueling demand for enhanced vaccination programs, with immunity from acellular vaccines known to wane substantially faster than that from whole-cell vaccines.
• In February 2026, ILiAD Biotechnologies secured an oversubscribed USD 115 million Series B round to advance development of its BPZE1 intranasal pertussis vaccine candidate, which has shown up to 90% prevention of bacterial colonization in Phase IIb data with no vaccine-related serious adverse events.
• GSK's Q3 2025 results showed BOOSTRIX generating USD 122 million in sales, supporting continued growth of its established vaccines portfolio.
• In the 7MM, PENTACEL leads in market size due to high-volume pediatric use, while BOOSTRIX shows strong growth potential driven by expanding booster and maternal immunization programs.
• Currently available vaccines in the 7MM include ADACEL, BOOSTRIX, HEXAXIM, VAXELIS, QUADRACEL, TETRABIK, TRIBIK/BK1301, and others, with key pipeline players including ILiAD Biotechnologies, Mitsubishi Tanabe Pharma Corporation, the Research Foundation for Microbial Diseases of Osaka University, and Cansino Bio.

Key Pertussis Companies
• Sanofi, GSK, Biken, KM Biologics, ILiAD Biotechnologies, Mitsubishi Tanabe Pharma Corporation, Cansino Bio, and others.

Key Pertussis Therapies
• ADACEL, BOOSTRIX, HEXAXIM/HEXYON/HEXACIMA, VAXELIS, PENTACEL, TETRABIK, TRIBIK/BK1301, BPZE1, DPT-IPV-Hib (BK-1310/MT-2355), DTcP, and others.
• The pertussis market is expected to grow due to increasing disease awareness and surveillance, waning immunity driving demand for booster vaccinations, and continued expansion of national immunization programs. The advancement of next-generation vaccine candidates, including intranasal and combination formulations, is expected to further shape competitive dynamics over the forecast period.

Pertussis Overview
Pertussis, commonly known as whooping cough, is an acute, highly contagious respiratory infection caused by Bordetella pertussis, characterized by a prolonged paroxysmal cough often accompanied by an inspiratory "whoop." Although traditionally considered a childhood disease, over half of reported cases now occur in adolescents and adults, largely due to waning immunity that declines to roughly 50% within 12 years post-vaccination. The disease progresses through catarrhal, paroxysmal, and convalescent stages, transmitted via respiratory droplets. Diagnosis relies on clinical presentation and is confirmed through PCR (most sensitive in early stages), culture, or serology, with early detection critical to limiting transmission.

Get a free sample for the Pertussis Market Forecast, Size & Share Analysis Report:https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Pertussis Market Segmentation
The pertussis market report proffers detailed analysis for the study period 2022-2036 segmented into:
• By Region/Geography: North America (US); Europe (Germany, France, Italy, Spain, and the UK); Asia-Pacific (Japan)
• By Drugs/Therapies
• By Epidemiology Segmentation: Total pertussis vaccination coverage

Download the report to understand which factors are driving pertussis market trends: https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Pertussis Treatment Landscape
Prevention remains the primary approach to managing pertussis, anchored by DTaP vaccination in children (given at 2, 4, 6, 15-18 months, and 4-6 years) and Tdap booster doses for adolescents and adults aged 10-64 years. Approved vaccines include ADACEL/REPEVAX (Sanofi), BOOSTRIX (GSK), HEXAXIM/HEXYON/HEXACIMA (Sanofi), and VAXELIS (Merck and Sanofi). For active infection, macrolide antibiotics such as azithromycin and clarithromycin remain the mainstay of treatment, particularly when started early, supported by hospitalization and supportive care for severe infant cases. Emerging pipeline candidates such as BPZE1 (ILiAD Biotechnologies) and DPT-IPV-Hib (Mitsubishi Tanabe Pharma Corporation) are advancing next-generation approaches, including intranasal delivery and expanded combination formulations.

Discover more about therapies set to grab major pertussis market share:https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Pertussis Market Strengths
• A broad, well-established base of approved Tdap booster and pediatric combination vaccines (ADACEL, BOOSTRIX, HEXAXIM, VAXELIS) supports strong global immunization coverage.
• Growing adoption of maternal immunization strategies is extending protection to newborns during their most vulnerable period.
• An active late-stage pipeline, led by BPZE1's intranasal mucosal immunity approach, is advancing next-generation prevention strategies beyond current acellular vaccines.

Pertussis Market Opportunities
• Waning immunity from acellular vaccines and recurring outbreaks are driving sustained demand for improved and longer-lasting booster and vaccine formulations.
• Expansion of national immunization programs and increasing recommendations for adolescent, adult, and maternal booster doses are opening growth opportunities across the 7MM, particularly in regions with low current booster compliance.

Scope of the Pertussis Market Report
•Study Period: 2022-2036
•Historical Year: 2022-2025 | Base Year: 2026 | Forecast Period: 2026-2036
•Coverage: The US; Germany, France, Italy, Spain, and the UK; Japan
•Key Companies: Sanofi, GSK, Biken, KM Biologics, ILiAD Biotechnologies, Mitsubishi Tanabe Pharma Corporation, Cansino Bio, and others
•Key Therapies: ADACEL, BOOSTRIX, HEXAXIM/HEXYON/HEXACIMA, VAXELIS, PENTACEL, TETRABIK, BPZE1, DPT-IPV-Hib, DTcP, and others
•Market CAGR (Forecast Period): 2.7% (2026-2036)
•Analysis Includes: KOL views, SWOT analysis, reimbursement, conjoint analysis, unmet needs, market drivers and barriers, epidemiology patient burden

To know more about pertussis companies working in the market, visit: https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Pertussis Market Report Introduction
2. Executive Summary for Pertussis
3. SWOT Analysis of Pertussis
4. Pertussis Market Overview at a Glance
5. Pertussis Disease Background and Overview
6. Pertussis Market Segmentation and Analysis
7. Regional Analysis of the Pertussis Market
8. Country-Specific Pertussis Market Analysis
9. Competitive Landscape and Key Company Profiles
10 Pertussis Unmet Needs
11 Pertussis Emerging Therapies and Pipeline
12 Pertussis Market Outlook
13 Pertussis Market Access and Reimbursement
14 Pertussis Market Drivers
15 Pertussis Market Barriers
16 Pertussis Recent Developments
17 Pertussis Appendix
18 Pertussis Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma and diagnostics companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.